JP2010285451A5 - - Google Patents

Download PDF

Info

Publication number
JP2010285451A5
JP2010285451A5 JP2010178286A JP2010178286A JP2010285451A5 JP 2010285451 A5 JP2010285451 A5 JP 2010285451A5 JP 2010178286 A JP2010178286 A JP 2010178286A JP 2010178286 A JP2010178286 A JP 2010178286A JP 2010285451 A5 JP2010285451 A5 JP 2010285451A5
Authority
JP
Japan
Prior art keywords
dosage form
agent
active agent
drugs
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010178286A
Other languages
English (en)
Other versions
JP2010285451A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010285451A publication Critical patent/JP2010285451A/ja
Publication of JP2010285451A5 publication Critical patent/JP2010285451A5/ja
Pending legal-status Critical Current

Links

Claims (12)

  1. 向かい合った主面表面を有し、
    (a) 少なくとも1種の有効薬剤の粒子と;
    (b) 少なくとも1種の薬学的に許容される水崩壊性または水溶性賦形剤とを含む急速崩壊固体投与剤型であって、
    (i)該投与剤型が、水性媒質と接触して約3分以内に崩壊または溶解し;
    (ii) 該投与剤型が、約2%以下の脆砕性を有し;かつ(iii)投与剤型の主面表面の各々が二重凸形状を形成する、上記投与剤型。
  2. 前記投与剤型が、水性媒質と接触して、約2分以内、約1分以内、約45秒以内、約30秒以内、約20秒以内、約15秒以内、約10秒以内、並びに約5秒以内からなる群より選択される時間内に実質的に崩壊または溶解する、請求項1に記載の投与剤型。
  3. 脆砕性が約1%以下である、請求項1または2に記載の投与剤型。
  4. (a) 前記二重凸形状表面が、投与剤型直径の約100〜約400%の長軸カップ半径と、投与剤型直径の約5〜約50%の短軸カップ半径を有する;または
    (b) 前記二重凸形状表面が、投与剤型直径の約240〜約290%の長軸カップ半径と、投与剤型直径の約16〜約28%の短軸カップ半径を有する、
    請求項1〜3のいずれか1項に記載の投与剤型。
  5. (a) 前記少なくとも1種の有効薬剤の濃度が、約0.1%〜99.9%(w/w)、約5%〜約70%(w/w)、並びに約20%〜約50%(w/w)からなる群より選択される;および/または、
    (b) 前記少なくとも1種の薬学的に許容される水崩壊性または水溶性賦形剤の濃度が、約99.9%〜約0.1%(w/w)、約95%〜約30%(w/w)、並びに約85%〜約60%(w/w)からなる群より選択される、
    請求項1〜のいずれか1項に記載の投与剤型。
  6. (a) 前記少なくとも1種の薬学的に許容される水崩壊性または水溶性賦形剤が、糖、糖アルコール、デンプン、天然ゴム、天然ポリマー、天然ポリマーの合成誘導体、合成ポリマー、及びこれらの混合物からなる群より選択される;または、
    (b) 前記少なくとも1種の薬学的に許容される水崩壊性または水溶性賦形剤が、ラクトース、グルコース、マンノース、マンニトール、ソルビトール、キシリトール、エリトリトール、ラクチトール、マルチトール、コーンデンプン、ジャガイモデンプン、トウモロコシデンプン、ゼラチン、カラギーナン、アルギン酸塩、デキストラン、マルトデキストラン、アラビアゴム、キサンタンゴム、ポリエチレングリコール、ポリビニルピロリドン、ポリビニルアルコール、ポリオキシエチレンコポリマー、ポリオキシプロピレンコポリマー、ポリエチレンオキシド、及びこれらの混合物からなる群より選択される、
    請求項1〜のいずれか1項に記載の投与剤型:。
  7. (a) 有効薬剤の粒子が、コーティング剤でコーティングされている;または
    (b) 有効薬剤の粒子が、コーティング剤でコーティングされ前記コーティング剤が約5〜約60%(w/w)の量で存在する、
    請求項1〜6のいずれかに記載の投与剤型。
  8. 前記少なくとも1種の有効薬剤が、
    (a) 難溶性であり;
    (b) 約2,000 nm以下の有効平均粒径を有し、
    (c) 有効薬剤の粒子の表面結合する少なくとも1種の表面安定剤を有する、
    請求項1〜のいずれか1項に記載の投与剤型。
  9. 前記表面安定剤が、非イオン表面安定剤、アニオン表面安定剤、カチオン表面安定剤、イオン性表面安定剤、および双性イオン表面安定剤からなる群より選択される、請求項に記載の投与剤型。
  10. 前記少なくとも1種の有効薬剤が、タンパク質、ペプチド、栄養剤、カロチノイド、抗肥満薬、コルチコステロイド、エラスターゼ阻害剤、鎮痛薬、抗真菌薬、腫瘍治療薬、制吐薬、鎮痛薬、心臓血管薬、抗炎症薬、駆虫薬、抗不整脈薬、抗生物質、抗凝固薬、抗うつ薬、抗糖尿病薬、鎮痙薬、抗ヒスタミン薬、抗高血圧薬、抗ムスカリン薬、抗ミコバクテリウム薬、抗新生物薬、免疫抑制薬、抗甲状腺薬、抗ウイルス薬、抗不安鎮静薬、収れん薬、β-アドレナリン受容体遮断剤、血液産物および置換物、強心薬、造影剤、咳抑制薬、診断薬、診断用撮像剤、利尿薬、ドーパミン作用薬、止血薬、免疫薬、脂質調節薬、筋弛緩薬、副交感神経刺激作用薬、上皮小体カルシトニンおよびビホスホネート、プロスタグランジン、放射性薬品、性ホルモン、抗アレルギー薬、興奮薬および食欲抑制薬、交感神経刺激作用薬、甲状腺薬、血管拡張薬、キサンチン、ニキビ治療薬、α-ヒドロキシ製剤、嚢胞性繊維症治療薬、喘息治療薬、気腫治療薬、呼吸窮迫症候群治療薬、慢性気管支炎治療薬、慢性閉塞性肺疾患治療薬、器官移植拒絶治療薬、結核症およびその他の肺感染症の治療薬、並びに後天性免疫不全症候群に関連する呼吸疾患治療薬からなる群より選択される、請求項1〜のいずれか1項に記載の投与剤型。
  11. 薬剤の調製のための、請求項1〜10のいずれかに記載の投与剤型の使用。
  12. (a) 少なくとも1種の有効薬剤の粒子と少なくとも1種の薬学的に許容される水崩壊性または水溶性賦形剤とを含む組成物を用意し、
    (b) 固体投与剤型を形成する
    工程を含む、請求項1〜10のいずれかに記載の急速崩壊固体投与剤型を製造する方法であって、
    該投与剤型が、(i) 水性媒質と接触して約3分以内に実質的に崩壊または溶解し;(ii) 約2%以下の脆砕性を有し;かつ(iii) 上記投与剤型が、各々二重凸形状を形成する、向かい合った主面表面を備える、上記方法。
JP2010178286A 2002-03-20 2010-08-09 脆砕性の低い急速溶解投与剤型 Pending JP2010285451A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36552602P 2002-03-20 2002-03-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003577853A Division JP2005526095A (ja) 2002-03-20 2003-03-20 脆砕性の低い急速溶解投与剤型

Publications (2)

Publication Number Publication Date
JP2010285451A JP2010285451A (ja) 2010-12-24
JP2010285451A5 true JP2010285451A5 (ja) 2011-11-04

Family

ID=28454670

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003577853A Withdrawn JP2005526095A (ja) 2002-03-20 2003-03-20 脆砕性の低い急速溶解投与剤型
JP2010178286A Pending JP2010285451A (ja) 2002-03-20 2010-08-09 脆砕性の低い急速溶解投与剤型

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003577853A Withdrawn JP2005526095A (ja) 2002-03-20 2003-03-20 脆砕性の低い急速溶解投与剤型

Country Status (6)

Country Link
US (1) US20030215502A1 (ja)
EP (1) EP1487419A2 (ja)
JP (2) JP2005526095A (ja)
AU (1) AU2003222027A1 (ja)
CA (1) CA2479735C (ja)
WO (1) WO2003080023A2 (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
BRPI0412273B1 (pt) * 2003-07-03 2019-09-24 The University Court Of The University Of St. Andrews Preparação farmacêutica, uso de um material de zeólito, artigo médico, produto cosmético e/ou de higiene pessoal, e, método de liberação de óxido nítrico
WO2005044006A1 (en) * 2003-11-05 2005-05-19 Battelle Memorial Institute Quick dissolving agrochemical products
JP4547161B2 (ja) * 2004-01-22 2010-09-22 エスエス製薬株式会社 用時溶解型速溶性固形製剤
US8242182B2 (en) * 2004-01-28 2012-08-14 Iota Nanosolutions Limited Porous bodies and method of production thereof
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
JP2009517485A (ja) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
JP5373283B2 (ja) * 2005-07-08 2013-12-18 武田薬品工業株式会社 錠剤
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
EA015682B1 (ru) * 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
EP1978939A2 (en) * 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
SG170047A1 (en) 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
AU2007325628A1 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US20080187628A1 (en) * 2007-02-02 2008-08-07 Champion Melinda L Water-Soluble, Quick-Dissolve Flavor Tablets
EP1977734A1 (en) * 2007-04-03 2008-10-08 Royal College of Surgeons in Ireland A method of producing fast dissolving tablets
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2009042809A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
MY169761A (en) * 2007-11-07 2019-05-15 Rigel Pharmaceuticals Inc Wet granulation using a water sequestering agent
ME01256B (me) * 2008-07-21 2013-06-20 Dr Falk Pharma Gmbh Farmaceutska formulacija za lečenje gornjeg digestivnog trakta
US20100120776A1 (en) * 2008-11-12 2010-05-13 Hall Bioscience Corporation Carbocysteine medical foods
EP2253306A1 (en) 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
US20110105441A1 (en) * 2009-10-30 2011-05-05 Fmc Corporation Stable Orally Disintegrating Tablets Having Low Superdisintegrant
JP5886530B2 (ja) * 2010-02-26 2016-03-16 第一三共株式会社 錠剤
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
JP5771381B2 (ja) * 2010-10-22 2015-08-26 アサヒフードアンドヘルスケア株式会社 乾燥酵母を含有する錠剤
JP5689173B2 (ja) * 2011-05-25 2015-03-25 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠
US20140141078A1 (en) * 2012-09-15 2014-05-22 Jeffery K. Slaboden Dissolvable TableT
LT2886108T (lt) 2013-12-23 2019-03-25 Dr. Falk Pharma Gmbh Optimizuota farmacinė kompozicija, skirta stemplės uždegiminių pakitimų gydymui
JP6379884B2 (ja) * 2014-09-03 2018-08-29 ニプロ株式会社 口腔内崩壊錠、及び口腔内崩壊錠の製造方法
JP6418878B2 (ja) * 2014-10-02 2018-11-07 ライオン株式会社 経口投与用錠剤
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US11135157B2 (en) 2018-05-17 2021-10-05 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the throat
US11096895B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet suitable for active pharmaceutical ingredients
US11052047B2 (en) 2018-05-17 2021-07-06 Fertin Pharma A/S Oral tablet suitable for fast release of active pharmaceutical ingredients
US11090263B2 (en) 2018-05-22 2021-08-17 Fertin Pharma A/S Tableted chewing gum suitable for active pharmaceutical ingredients
US11096896B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Tablet dosage form for buccal absorption of active ingredients
US20190350858A1 (en) 2018-05-17 2019-11-21 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the gastrointestinal tract
US11096894B2 (en) * 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
CA1195251A (en) * 1981-07-20 1985-10-15 Anthony B.J. Eoga Convex tablet configuration
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU2317592A (en) * 1991-07-05 1993-02-11 University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
DE4203932A1 (de) * 1992-02-11 1993-08-12 Deutsche Aerospace Sende-/empfangsmodul
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
ATE208615T1 (de) * 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) * 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
GB9421836D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) * 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) * 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5807577A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
ES2172793T3 (es) 1996-06-17 2002-10-01 Janssen Pharmaceutica Nv Formas de dosificacion biconvexas de desintegracion rapida.
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
IN190906B (ja) * 1998-04-03 2003-08-30 Kyowa Hakko Kogyo Company Ltd
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
JP4156807B2 (ja) * 1999-06-01 2008-09-24 エラン ファーマ インターナショナル,リミティド 小型ミル及びその方法
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6465615B1 (en) 2001-09-10 2002-10-15 Astrazeneca Ab Monohydrate lisinopril

Similar Documents

Publication Publication Date Title
JP2010285451A5 (ja)
JP2005526095A5 (ja)
JP3404648B2 (ja) 速崩壊性固形製剤
TWI263507B (en) Cilostazol preparation
JP4749668B2 (ja) 高い均質性を有する口内分散性錠剤及びその調製方法
US20030096791A1 (en) Taste masking of highly water-soluble drugs
JP2011037876A (ja) 迅速崩壊固体経口投与形態
US20090130213A1 (en) Rapidly disintegrating solid oral dosage form
CN102740893B (zh) 压制包衣的口腔崩解片剂
US7846460B2 (en) Composition comprising a mixture of active principles, and method of preparation
JP2005526095A (ja) 脆砕性の低い急速溶解投与剤型
US20060093679A1 (en) Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve
JP2008517988A (ja) 不眠症の治療において有用な新規な製剤処方
JP2006070046A (ja) 速崩壊性固形製剤
US20150272889A1 (en) Orally Disintegrating Tablet
JP5824524B2 (ja) ヒドロキシアルキルセルロース微粒子を含有する口腔内崩壊錠
CN103976997A (zh) 一种降血糖复方缓释胶囊及其制备方法
CN114886874A (zh) 口腔速溶膜剂及其制备方法
US10111832B2 (en) Orodispersible tablets obtained by compression molding
JP5566757B2 (ja) 固形製剤
JP2012508786A (ja) 活性成分の粒状物質を製造する新規の方法、及びそれにより得られた粒状物質
JPH083066A (ja) かぜ薬製剤
JP5764811B2 (ja) 固形製剤
KR100790056B1 (ko) 경구용 입제제(粒製劑)
JP2004217566A (ja) 製剤のゲル強度の増強方法および徐放性製剤